Turn Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
GX-03, a novel topical therapy, demonstrated strong efficacy and safety in phase II eczema trials, with rapid onset and no adverse events. The company is expanding into toenail fungus and other inflammatory indications, supported by robust IP, a lean operation, and a strong leadership team.
-
A novel polymer-based ointment targeting IL-36/IL-31 is in phase II trials for moderate to severe eczema, with interim and top-line data expected in Q2 2026. The company also advances a phase III-ready onychomycosis drug and explores additional dermatology indications, supported by strong safety data and patent protection.
-
The company is advancing a novel topical therapy for moderate to severe eczema, with a large phase II trial underway and interim results expected in Q2 2026. Its lead asset, GX-03, shows strong safety and efficacy, with plans for phase III trials in both eczema and onychomycosis.